A Study of MZE782 in Adults With PKU
NCT07694440 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38
Last updated 2026-08-20
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of MZE782 in adults with Phenylketonuria (PKU).
Conditions
- Phenylketonuria (PKU)
Interventions
- DRUG
-
MZE782
Tablet, Low Dose
- OTHER
-
Placebo
Tablet
- DRUG
-
MZE782
Tablet, High Dose
Sponsors & Collaborators
-
Maze Therapeutics
lead INDUSTRY
Principal Investigators
-
Medical Director · Maze Therapeutics
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-06-23
- Primary Completion
- 2027-12-31
- Completion
- 2028-02-29
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria
NCT07241234 ·Status: RECRUITING ·Phase: PHASE1
-
Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy
NCT04281485 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.
NCT06549400 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)
NCT02579239 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2
NCT06523400 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
NCT07281079 ·Status: RECRUITING ·Phase: PHASE3
-
Microdystrophin Gene Transfer Study in Adolescents and Children With DMD
NCT03368742 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Gene Therapy with Modified Autologous Hematopoietic Stem Cells for Patients with Mucopolysaccharidosis Type IIIA
NCT04201405 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy
NCT03508947 ·Status: COMPLETED ·Phase: PHASE1
-
Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2
NCT02704325 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy
NCT02603562 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Tolerability of RTX-134 in Adults With Phenylketonuria
NCT04110496 ·Status: TERMINATED ·Phase: PHASE1
-
A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome
NCT02126995 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)
NCT02230566 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
NCT07160634 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy
NCT03692312 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome
NCT07135050 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)
NCT03769116 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
NCT00577577 ·Status: COMPLETED ·Phase: PHASE2
-
A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D)
NCT01976091 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
NCT03772587 ·Status: COMPLETED ·Phase: PHASE2
-
A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.
NCT07266324 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis
NCT04713475 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease
NCT05758922 ·Status: COMPLETED ·Phase: PHASE2
-
PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)
NCT07429240 ·Status: RECRUITING ·Phase: PHASE1/PHASE2